# Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Canonical URL: https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants
Ticker: TSHA
Company: Taysha Gene Therapies
Source: Taysha Gene Therapies
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.tayshagtx.com
## Summary

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today

## Article Body
DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today
## Recent Company News
- 2026-06-25 20:01 EST — [Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-multiple-presentations-highlighting-its-tsha-102-4055adda) — Source: Taysha Gene Therapies
- 2026-06-25 13:46 EST — [Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants) — Source: Taysha Gene Therapies
- 2026-06-25 13:46 EST — [Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants) — Source: Taysha Gene Therapies
- 2026-06-25 13:46 EST — [Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-completion-of-dosing-in-reveal-pivotal-trial-and-reports-longer-term-clinical-data-from-part-a-of-reveal-phase-1-2-trials-evaluating-tsha-102-for-rett-syndrome) — Source: Taysha Gene Therapies
- 2026-06-25 13:46 EST — [Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-progress-across-tsha-102-pivotal-gene-therapy-program-in-rett-syndrome) — Source: Taysha Gene Therapies
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)